110 related articles for article (PubMed ID: 6410041)
1. Kinetic study on disappearance of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide (DN-1417) from plasma using a radioimmunoassay for DN-1417 isobutylamide.
Oshima I; Saito S; Shiota K; Miyake A; Oka Y; Nakayama R
J Pharmacobiodyn; 1983 Mar; 6(3):202-8. PubMed ID: 6410041
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunoassay for an analog of thyrotrophin-releasing hormone, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide (DN-1417).
Shiota K; Miyake A; Tsunoda C; Oka Y; Nagawa Y; Nakayama R
J Immunol Methods; 1982; 51(1):69-80. PubMed ID: 6809831
[TBL] [Abstract][Full Text] [Related]
3. [A TRH analog (DN-1417). Blood level and brain distribution determined by radioimmunoassay after intravenous administration in rats].
Nagai Y; Narumi S; Saji Y; Nagawa Y
Nihon Yakurigaku Zasshi; 1985 Apr; 85(4):231-42. PubMed ID: 3924797
[TBL] [Abstract][Full Text] [Related]
4. Absorption of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide citrate (DN-1417), an analog of thyrotropin-releasing hormone, in rats and dogs.
Yokohama S; Yoshioka T; Kitamori N
J Pharmacobiodyn; 1984 Aug; 7(8):527-35. PubMed ID: 6439851
[TBL] [Abstract][Full Text] [Related]
5. Intracerebroventricular injection of a TRH analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-prolinamide, induces gastric lesions and gastric acid stimulation in rats.
Maeda-Hagiwara M; Watanabe H
Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):142-6. PubMed ID: 3930976
[TBL] [Abstract][Full Text] [Related]
6. Intestinal absorption mechanisms of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide citrate (DN-1417) and thyrotropin-releasing hormone (TRH).
Yokohama S; Yoshioka T; Kitamori N; Shimamoto T; Kamada A
J Pharmacobiodyn; 1985 Apr; 8(4):278-85. PubMed ID: 3928869
[TBL] [Abstract][Full Text] [Related]
7. Effects of thyrotropin releasing hormone and its analogue, DN 1417, on biopterin concentration and tryptophan hydroxylation in rat raphe slices.
Sawada M; Hirata Y; Minami M; Nagatsu T
Life Sci; 1987 Dec; 41(25):2733-7. PubMed ID: 3121968
[TBL] [Abstract][Full Text] [Related]
8. [Effect of DN-1417 on ataxia in Rolling mouse Nagoya and Staggerer mouse in comparison with the effect of TRH].
Matsui K; Mano Y; Ando K
Yakubutsu Seishin Kodo; 1986 Jun; 6(2):281-3. PubMed ID: 3096012
[TBL] [Abstract][Full Text] [Related]
9. Increase in rat regional brain cyclic nucleotides by thyrotropin-releasing hormone (TRH) and its analog DN-1417.
Narumi S; Nagai Y; Saji Y; Nagawa Y
Jpn J Pharmacol; 1983 Oct; 33(5):915-26. PubMed ID: 6139495
[TBL] [Abstract][Full Text] [Related]
10. A radioimmunoassay for TA-0910, a new metabolically stable thyrotrophin-releasing hormone analogue.
Chishima S
J Pharm Biomed Anal; 1994 Jun; 12(6):795-804. PubMed ID: 7918782
[TBL] [Abstract][Full Text] [Related]
11. Effects of thyrotropin releasing hormone and its analogues on unconsciousness following head injury in mice.
Tanaka K; Ogawa N; Chou H; Mori A; Yanaihara N
Regul Pept; 1992 Mar; 38(2):129-33. PubMed ID: 1574607
[TBL] [Abstract][Full Text] [Related]
12. Gamma-butyrolactone-gamma-carbonyl-histidyl-prolinamide citrate (DN-1417): a novel TRH analog with potent effects on the central nervous system.
Miyamoto M; Fukuda N; Narumi S; Nagai Y; Saji Y; Nagawa Y
Life Sci; 1981 Feb; 28(8):861-9. PubMed ID: 6783804
[No Abstract] [Full Text] [Related]
13. In vitro thyrotrophin release with thyrotropin-releasing hormone and an analogue, DN-1417.
Shiota K; Yoshida K; Noguchi C; Nakayama R
Acta Endocrinol (Copenh); 1984 May; 106(1):71-8. PubMed ID: 6428117
[TBL] [Abstract][Full Text] [Related]
14. Potential anti-depressive effects of thyrotropin releasing hormone (TRH) and its analogues.
Ogawa N; Mizuno S; Mori A; Nukina I; Ota Z; Yamamoto M
Peptides; 1984; 5(4):743-6. PubMed ID: 6436797
[TBL] [Abstract][Full Text] [Related]
15. A possible mechanism of action of thyrotropin-releasing hormone (TRH) and its analog DN-1417 on the release of dopamine from the nucleus accumbens and striatum in rats.
Narumi S; Nagai Y; Saji Y; Nagawa Y
Jpn J Pharmacol; 1985 Dec; 39(4):425-35. PubMed ID: 2869169
[TBL] [Abstract][Full Text] [Related]
16. Plasma clearance and plasma half-disappearance time of exogenous thyrotropin-releasing hormone and pyroglutamyl-N3im-methyl-histidyl prolineamide.
Morley JE; Garvin TJ; Pekary AE; Utiger RD; Nair MG; Baugh CM; Hershman JM
J Clin Endocrinol Metab; 1979 Mar; 48(3):377-80. PubMed ID: 107180
[TBL] [Abstract][Full Text] [Related]
17. TRH and its novel analog (DN-1417): antipentobarbital action and involvement of cholinergic mechanisms.
Miyamoto M; Nagai Y; Narumi S; Saji Y; Nagawa Y
Pharmacol Biochem Behav; 1982 Oct; 17(4):797-806. PubMed ID: 6817348
[TBL] [Abstract][Full Text] [Related]
18. Antiepileptic effects of thyrotropin-releasing hormone and its new derivative, DN-1417, examined in feline amygdaloid kindling preparation.
Sato M; Morimoto K; Wada JA
Epilepsia; 1984 Oct; 25(5):537-44. PubMed ID: 6434294
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin-releasing hormone (TRH) and its analog (DN-1417): interaction with pentobarbital in oxygen consumption and cyclic AMP formation of rat cerebral cortex slices.
Narumi S; Nagai Y; Saji Y; Nagawa Y
Life Sci; 1984 May; 34(22):2177-84. PubMed ID: 6328158
[TBL] [Abstract][Full Text] [Related]
20. A TRH analog (DN-1417): effects on local cerebral glucose utilization in conscious and pentobarbitalized rats determined by the autoradiographic 2-deoxy-[14C]glucose method.
Nagai Y; Narumi S; Miyamoto M; Saji Y; Nagawa Y
Jpn J Pharmacol; 1983 Jun; 33(3):635-45. PubMed ID: 6413736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
